Treatment strategies and cumulative live birth rates in WHO-II ovulation disorders-Reference-Cited by-同舟云学术

Treatment strategies and cumulative live birth rates in WHO-II ovulation disorders

Published:2018-06 Issue: Volume:225 Page:84-89
ISSN:0301-2115
Container-title:European Journal of Obstetrics & Gynecology and Reproductive Biology
language:en
Short-container-title:European Journal of Obstetrics & Gynecology and Reproductive Biology

Author:

Braam Sanne C.,de Bruin Jan Peter,Buisman Erato T.I.A.,Brandes Monique,Nelen Willianne L.D.M.,Smeenk Jesper M.J.,van der Steeg Jan Willem,Mol Ben Willem J.,Hamilton Carl J.C.M.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Reproductive Medicine

Reference27 articles.

1. Health and fertility in World Health Organization group 2 anovulatory women;ESHRE Capri Workshop Group;Hum Reprod Update,2012

2. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome;Legro;N Engl J Med,2014

3. Consensus on infertility treatment related to polycystic ovary syndrome;Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group;Fertil Steril,2008

4. Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis;Misso;Hum Reprod Update,2012

5. Aromatase inhibitors for subfertile women with polycystic ovary syndrome;Franik;Cochrane Database Syst Rev,2014

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strong social disparities in access to IVF/ICSI despite free cost of treatment: a French population-based nationwide cohort study;BMC Women's Health;2023-11-22

2. Trends in clomiphene citrate and gonadotropins use in women with infertility between 2010 and 2017: A population‐based study in France;Pharmacoepidemiology and Drug Safety;2023-03-26

3. Clinical outcomes in patients receiving originator follitropin alfa and follitropin alfa biosimilars in real-world clinical practice: A retrospective study;Journal of Human Reproductive Sciences;2023

4. Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry;Best Practice & Research Clinical Obstetrics & Gynaecology;2022-12

5. Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions;International Journal of Molecular Sciences;2022-06-17